Objetivo ALK positive cancer such as Anaplastic Large Cell Lymphoma (ALCL), Non small Cell Lung Carcinoma (NSCLC) and neuroblastoma are important cancers of children and adults, currently treated with standard chemotherapy and radiotherapy, with unpredicatable and poor results, in particular in the case of NSCLC and neuroblastoma. In August 2011, the US Food and Drug Administration (FDA) had an accelerated approval of a novel drug (called Crizotinib) to treat NSCLC that express abnormal ALK protein. Phase II and III clinical trials are ongoing to test the same drug in ALCL and neuroblastoma. However, it is now clear that the treatment with Crizotinib has a good initial efficacy and response, but the cancer inevitably relapses because of the occurrence of drug resistance. This resistance is due to selection of ALK point mutants that no longer bind the inhibitor. New drugs to tame the resistant cells will be probably developed in the future (as happened for Gleevec and second and third generation of BCR-ABL inhibitors), but it is expected that again resistance will emerge.As part of a research conducted under an ERC Starting Grat, we developed a new therapy for ALK positive ALCL, NSCLC and neuroblastoma based on the generation of a potent and specific anti-tumor response based on the development of an ALK-targeted immune response. This specific anti-ALK immune response is achieved by an anti-ALK vaccination in preclinical mouse models of ALCL and NSCLC. Now, in this Proof-of-Concept grant, we propose to take the next steps to move our invention toward a clinical application in human patients, by testing GLP formulations of the vaccine, its potential toxic effects and by searching the market for companies interested in its development and commercialization. Our goal is to understand and finalize the best strategy to move this experimental therapy to the market and generate a partnership with a pharma company. Ámbito científico medical and health sciencesclinical medicineoncologylung cancermedical and health sciencesbasic medicineimmunologymedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines Programa(s) FP7-IDEAS-ERC - Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) Tema(s) ERC-OA-2012-PoC - European Research Council ERC Proof of Concept Convocatoria de propuestas ERC-2012-PoC Consulte otros proyectos de esta convocatoria Régimen de financiación CSA-SA(POC) - Supporting action (Proof of Concept) Institución de acogida UNIVERSITA DEGLI STUDI DI TORINO Aportación de la UE € 74 586,35 Dirección VIA GIUSEPPE VERDI 8 10124 Torino Italia Ver en el mapa Región Nord-Ovest Piemonte Torino Tipo de actividad Higher or Secondary Education Establishments Contacto administrativo Antonietta Davello (Ms.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos Beneficiarios (2) Ordenar alfabéticamente Ordenar por aportación de la UE Ampliar todo Contraer todo UNIVERSITA DEGLI STUDI DI TORINO Italia Aportación de la UE € 74 586,35 Dirección VIA GIUSEPPE VERDI 8 10124 Torino Ver en el mapa Región Nord-Ovest Piemonte Torino Tipo de actividad Higher or Secondary Education Establishments Contacto administrativo Antonietta Davello (Ms.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos META GROUP SRL Italia Aportación de la UE € 75 352,61 Dirección VIALE UMBERTO TUPINI 116 00144 Roma Ver en el mapa Región Centro (IT) Lazio Roma Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Contacto administrativo Anna Amati (Ms.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos